Severe Lung Failure

Abiomed Breethe OXY-1 System™ Provides Cardiopulmonary Support for Heart and Lung Failure Patients

Patients presenting with clinical pulmonary or cardiac deterioration require additional oxygen delivery, and traditional techniques such as mechanical ventilation, invasive hemodynamic monitoring, and inotropic support. The OXY-1 System can help serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS or COVID-19.

Cardiopulmonary Bypass

A clinical team effort is essential for successful cardiopulmonary bypass for patients experiencing cardiogenic shock or respiratory failure. The OXY-1 System can help to manage your critically-ill cardiac and pulmonary patients, ultimately allowing for circulatory support to help your patient recover or bridge to another therapy such as LVAD or transplantation. The OXY-1 System can be used in both veno-venous (V-V) and veno-arterial (V-A) configurations for either cardiogenic shock or acute respiratory distress syndrome (ARDS).

The OXY-1 System must be operated and/or monitored by users with specialized training in extracorporeal circulation therapy. These users include perfusionists, extracorporeal circulation specialists, ICU nurses with specialized extracorporeal circulation training, cardiothoracic surgeons, intensivists and others with specialized training and experience. Users need to be knowledgeable and experienced in cardiopulmonary bypass and mechanical circulatory support.

Highlights of the OXY-1 System

The components of the OXY-1 System are designed to reduce the overall equipment footprint, support transition from bed to ambulation via system portability and provide an intuitive interface for health care professionals to set up and manage. The integrated pump lung unit is engineered with volute spiral technology for uniform blood flow with minimal stagnation and advanced gas exchange technology that allows for full therapy with reduced oxygen requirements.

BRE-0016